Fundraising Fox
/Companies
Sign in

Ocugen

NASDAQ: OCGN

Malvern, US · Founded 2013 · Delaware corporation

Find your way into Ocugen

Sign up to see every warm intro you have to Ocugen

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Ocugen team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Ocugen develops gene therapies, including a modifier gene therapy platform aimed at treating inherited retinal diseases and blindness. The company focuses on addressing unmet medical needs in vision-related and eye diseases.

BiotechMedical Devices

Founders & leadership

Ocugen was founded in 2013 by Shankar Musunuri.

SM
Shankar MusunuriFounder
CK
Charles KangExecutive
UK
Uday KompellaNamed on SEC filing

Board

RA
Ravi AcharBoard director

Reported raises · per SEC filings

Form D private placements

$27.2M disclosed across 6 of 9 rounds · 1900–2026

▶$350.4KraisedNov 2018 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Susan DrexlerExecutive Officer
  • Daniel JorgensenExecutive Officer
  • Uday KompellaDirector, Promoter
  • Frank LeoDirector
  • Holdings KVMPromoter
  • John ZhangDirector
  • Manish PottiDirector
  • Shankar MusunuriExecutive Officer, Director
  • Halit Suha TaspolatogluDirector
  • Martin CoyneDirector
Offering amount
$4M
Amount sold
$350.4K
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedFeb 2018 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Uday KompellaDirector, Promoter
  • Charles KangExecutive Officer
  • Daniel JorgensenExecutive Officer
  • Halit Suha TaspolatogluDirector
  • John ZhangDirector
  • Manish PottiDirector
  • Shankar MusunuriExecutive Officer, Director
  • Holdings KVMPromoter
  • Ravi AcharDirector
  • Frank LeoDirector
Offering amount
$5M
Amount sold
$5M
Proceeds to insiders
$5M
First sale
Feb 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.5MraisedJun 2017 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mannish PottiDirector
  • Ravi AcharDirector
  • Uday KompellaExecutive Officer, Director, Promoter
  • Holdings KVMPromoter
  • Frank LeoDirector
  • Shankar MusunuriExecutive Officer, Director
  • Charles KangExecutive Officer
  • Junge ZhangDirector
Offering amount
$7.5M
Amount sold
$7.5M
Minimum investment
$20K
Proceeds to insiders
$7.5M
First sale
May 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedFeb 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shankar MusunuriExecutive Officer, Director, Promoter
Offering amount
$200K
Amount sold
$200K
Minimum investment
$35K
Proceeds to insiders
$200K
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedFeb 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Uday KompellaDirector
  • Ravi AcharDirector
  • KVM KVM Holdings, LLCPromoter
  • Charles KangExecutive Officer, Director
  • Shankar MusunuriExecutive Officer, Director, Promoter
Offering amount
$6M
Amount sold
$6M
Minimum investment
$20K
Proceeds to insiders
$6M
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Ocugen do?
Ocugen develops gene therapies, including a modifier gene therapy platform aimed at treating inherited retinal diseases and blindness. The company focuses on addressing unmet medical needs in vision-related and eye diseases.
Who founded Ocugen?
Ocugen was founded by Shankar Musunuri in 2013.
How much funding has Ocugen raised?
Ocugen has disclosed $27.2M raised across 6 of its 9 known rounds.
Where is Ocugen headquartered?
Ocugen is headquartered in Malvern, US.